NCT02562573View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Type 2 DiabetesMetabolic Syndrome
Interventions
DRUG

PBI4050

Trial Locations (1)

Unknown

Edmonton

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY